Global Myocarditis Pipeline Report 2016 - Therapeutics Review of 2 Companies & 7 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Myocarditis - Pipeline Review, H2 2016" report to their offering.

Myocarditis pipeline therapeutics constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by Companies and remaining by the Universities Institutes.

Our latest report Myocarditis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue.

Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body. The molecules developed by Companies in Preclinical stages are 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Myocarditis Overview
  3. Therapeutics Development
  4. Pipeline Products for Myocarditis - Overview
  5. Pipeline Products for Myocarditis - Comparative Analysis
  6. Myocarditis - Therapeutics under Development by Companies
  7. Myocarditis - Therapeutics under Investigation by Universities/Institutes
  8. Myocarditis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Myocarditis - Products under Development by Companies
  13. Myocarditis - Products under Investigation by Universities/Institutes
  14. Myocarditis - Companies Involved in Therapeutics Development
  • CEL-SCI Corporation
  • GlaxoSmithKline Plc

For more information about this report visit http://www.researchandmarkets.com/research/m45xmg/myocarditis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs